Evidence map›Paper›PMID 33113526›Full record

Trial reportNeonatology2020

High-Dose Erythropoietin in Extremely Low Gestational Age Neonates Does Not Alter Risk of Retinopathy of Prematurity.

Dennis E Mayock, Zimeng Xie, Bryan A Comstock, Patrick J Heagerty, Sandra E Juul, Preterm Epo Neuroprotection (PENUT) Trial Consortium

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neonatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Erythropoietin and retinopathy of prematurity: a retrospective cohort study in Japan, 2008-2018.Journal of perinatology : official journal of the California Perinatal Association · 2024
    Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Dennis E MayockDivision of Neonatology, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA, mayock@uw.edu.
Zimeng XieDivision of Biomedical Statistics, Department of Biostatistics, University of Washington, Seattle, Washington, USA.
Bryan A ComstockDivision of Biomedical Statistics, Department of Biostatistics, University of Washington, Seattle, Washington, USA.
Patrick J HeagertyDivision of Biomedical Statistics, Department of Biostatistics, University of Washington, Seattle, Washington, USA.
Sandra E JuulDivision of Neonatology, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.
Preterm Epo Neuroprotection (PENUT) Trial Consortium
University of Washington · US

Funding

Preterm Epo Neuroprotection Trial (PENUT Trial) CCCU01NS077953 · NINDS · UNIVERSITY OF WASHINGTON · PI JUUL, SANDRA E · 2013 to 2018
$10.7M
Mechanisms of Brain Dysmorphology in MN1 C-Terminal Truncation Syndrome, a Novel Intellectual Developmental Disability Disorder P50HD103524 · NICHD · UNIVERSITY OF WASHINGTON · PI Sandra E Juul · 2020 to 2026
$9.9M
Preterm Epo Neuroprotection Trial (PENUT Trial) DCCU01NS077955 · NINDS · UNIVERSITY OF WASHINGTON · PI HEAGERTY, PATRICK J · 2013 to 2018
$1.5M
NICHD NIH HHS P50 HD103524NINDS NIH HHS U01 NS077953NINDS NIH HHS U01 NS077955
6 · The paper itself

Abstract

introductionThe Preterm Erythropoietin (Epo) Neuroprotection (PENUT) Trial sought to determine the safety and efficacy of early high-dose Epo as a potential neuroprotective treatment. We hypothesized that Epo would not increase the incidence or severity of retinopathy of prematurity (ROP).

methodsA total of 941 infants born between 24-0/7 and 27-6/7 weeks' gestation were randomized to 1,000 U/kg Epo or placebo intravenously for 6 doses, followed by subcutaneous or sham injections of 400 U/kg Epo 3 times a week through 32 weeks post-menstrual age. In this secondary analysis of PENUT trial data, survivors were evaluated for ROP. A modified intention-to-treat approach was used to compare treatment groups. In addition, risk factors for ROP were evaluated using regression methods that account for multiples and allow for adjustment for treatment and gestational age at birth.

resultsOf 845 subjects who underwent ROP examination, 503 were diagnosed with ROP with similar incidence and severity between treatment groups. Gestational age at birth, birth weight, prenatal magnesium sulfate, maternal antibiotic exposure, and presence of heart murmur at 2 weeks predicted the development of any ROP, while being on high-frequency oscillator or high-frequency jet ventilation (HFOV/HFJV) at 2 weeks predicted severe ROP.

conclusionEarly high-dose Epo followed by maintenance dosing through 32 weeks does not increase the risk of any or severe ROP in extremely low gestational age neonates. Gestational age, birth weight, maternal treatment with magnesium sulfate, antibiotic use during pregnancy, and presence of a heart murmur at 2 weeks were associated with increased risk of any ROP. Treatment with HFOV/HFJV was associated with an increased risk of severe ROP.

Indexed as

ErythropoietinInfant, Low Birth WeightRetinopathy of PrematurityFemaleGestational AgeHumansInfantInfant, NewbornInfant, PrematureMalePregnancyRisk FactorsErythropoietinErythropoietinExtreme prematurityRetinopathy of prematurity

Identifiers

PMID33113526
PMCPMC7855231
OpenAlexW3096436987

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.